Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi.

六家生物技术初创公司正在合并为一家名为Alys Pharmaceuticals的新皮肤药物开发公司，该公司于周一从欧洲生命科学投资公司Medicxi斥资1亿美元成立。

Alys was formed out of the merger of a group of biotechs hatched in recent years by Medicxi: Granular Therapeutics, Aldena Therapeutics, Nira Biosciences, Graegis Pharmaceuticals and Vimela Therapeutics. They’ve been combined to create a larger company with a broad pipeline of experimental dermatology medicines..

Alys是由Medicxi近年来孵化的一组生物技术公司合并而成的：颗粒状治疗公司、Aldena治疗公司、Nira生物科学公司、Graegis制药公司和Vimela治疗公司。他们联合起来创建了一家规模较大的公司，拥有广泛的实验性皮肤病药物渠道。。

The company is starting out with a dozen programs in preclinical testing, including potential treatments for atopic dermatitis and vitiligo. It’s currently run by Chief Operating Officer Thibaud Portal, a venture partner at Medicxi and longtime executive with Galderma.

该公司正在启动十几个临床前测试项目，包括特应性皮炎和白癜风的潜在治疗方法。它目前由首席运营官Thibaud Portal运营，Thibaud Portal是Medicxi的风险合伙人，也是Galderma的长期高管。

In forming Alys, Medicxi is using a familiar playbook. Three years ago, the company merged 10 of its portfolio companies into Centessa Pharmaceuticals and launched it with $250 million in funding. The concept was borne out of Medicxi’s “asset-centric” approach of investing in companies focused on one or two experimental medicines, rather than a broad drugmaking platform.

在组建Alys时，Medicxi使用了一本熟悉的剧本。三年前，该公司将其投资组合中的10家公司合并为Centessa Pharmaceuticals，并以2.5亿美元的资金启动。这一概念源于Medicxi的“以资产为中心”的方法，即投资于专注于一种或两种实验药物的公司，而不是一个广泛的制药平台。

Centessa, and now Alys, are examples of using that model on a broader scale..

Centessa和现在的Alys都是在更广泛的范围内使用该模型的例子。。

'We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology,” said Medicxi partner and Alys chairman Francesco De Rubertis, in a statement. “Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.'.

Medicxi合伙人兼Alys主席弗朗西斯科·德·鲁贝蒂斯（Francesco De Rubertis）在一份声明中表示：“我们相信，将多家以资产为中心的公司与一支非凡的团队聚集在一起，将推动Alys转变免疫皮肤病学的创新。”。“Alys管理着广泛的资产管道，具有不同的风险状况，并将从规模的变化和便利的资本获取中受益匪浅。”。

Alys intends to ask the Food and Drug Administration to begin human tests for all of the dozen medicines in its pipeline by the end of 2026, per its website. The company expects to have seven early-stage readouts by late that year, too.

Alys打算要求食品和药物管理局在2026年底之前，根据其网站，开始对其管道中的所有十几种药物进行人体测试。该公司预计到当年年底也将有七次早期读数。

The company is launching at a time when immune disease biotechs have become a hot commodity. Progress developing drugs for immunological disorders helped drive an uptick in dealmaking last year that some Wall Street analysts expect to continue.

该公司成立之际，免疫疾病生物技术已成为热门商品。免疫紊乱药物的开发进展推动了去年交易的增加，一些华尔街分析师预计交易会继续。